Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.
about
Treatment with intravenous pamidronate is a good alternative in case of gastrointestinal side effects or contraindications for oral bisphosphonates.Bone tissue engineering therapeutics: controlled drug delivery in three-dimensional scaffoldsParathyroid hormone versus bisphosphonate treatment on bone mineral density in osteoporosis therapy: a meta-analysis of randomized controlled trials.Once-monthly risedronate for postmenopausal osteoporosisIntravenous bisphosphonates for postmenopausal osteoporosis.Clinical utility of clodronate in the prevention and management of osteoporosis in patients intolerant of oral bisphosphonatesAssociation of Bisphosphonate Use and Risk of Revision After THA: Outcomes From a US Total Joint Replacement Registry.Medication burden of Saudi Arabian women receiving antiresorptive therapyLong-term use of bisphosphonates in osteoporosis.Suitability of liposomal carriers for systemic delivery of risedronate using the pulmonary route.Telephone counseling to improve osteoporosis treatment adherence: an effectiveness study in community practice settings.
P2860
Q33482516-C24EB170-9B64-4FEA-BDA4-0C02666AB6AFQ33742858-DC0B4138-5F62-4503-99CB-1D312647AB89Q34056218-A2AFAB14-355B-446E-B76B-2F967F14A847Q34272000-EBD18509-9DD7-40DE-8C52-68228181E537Q34863964-8D2121D3-2448-4812-830E-60AED01C2B01Q35533455-04BA6C11-938B-4772-B3C3-CDADD88F92A8Q36100929-D82836F2-4E4B-4B30-8C75-F91A9CBD0CA8Q36311638-3F6258EF-F2AD-4342-8F10-96CC93EEC0D7Q43267062-41EB9FE7-BC6C-419C-B781-AD4DBC758D3DQ45377441-5A74DC24-E5AB-4A2F-AF45-E2FF481E3E2EQ48375169-31FA2112-FEE4-4061-AB17-C83107F1ED90
P2860
Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Optimizing the management of p ...... role of intermittent therapy.
@ast
Optimizing the management of p ...... role of intermittent therapy.
@en
type
label
Optimizing the management of p ...... role of intermittent therapy.
@ast
Optimizing the management of p ...... role of intermittent therapy.
@en
prefLabel
Optimizing the management of p ...... role of intermittent therapy.
@ast
Optimizing the management of p ...... role of intermittent therapy.
@en
P1476
Optimizing the management of p ...... role of intermittent therapy.
@en
P2093
Paul D Miller
P304
P356
10.1016/J.CLINTHERA.2005.04.005
P577
2005-04-01T00:00:00Z